

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

Pediatric and Adult Patients with ME/CFS following COVID-19: A Structured Approach to Diagnosis Using the Munich Berlin Symptom Questionnaire (MBSQ)

Laura C. Peo^{1†}, Katharina Wiehler^{1†}, Johannes Paulick¹, Katrin Gerrer¹, Ariane Leone¹, Anja Viereck¹, Matthias Haegele¹, Silvia Stojanov¹, Cordula Warlitz¹, Silvia Augustin¹, Martin Alberer¹, Daniel B. R. Hattesoht², Laura Froehlich³, Carmen Scheibenbogen⁴, Lorenz Mihatsch¹, Rafael Pricoco^{1†}, Uta Behrends^{1,2†*}

¹ MRI Chronic Fatigue Center for Young People (MCFC), Children's Hospital, TUM School of Medicine, Technical University of Munich, Munich, Germany

² German Association for ME/CFS, Hamburg, Germany

³ Research Center CATALPA, FernUniversität in Hagen, Hagen, Germany

⁴ Charité Fatigue Center (CFC), Berlin, Germany

† These authors contributed equally to this work

*Corresponding author: uta.behrends@mri.tum.de

Short title: Pediatric ME/CFS post-COVID-19 assed by MBSQs

1 **ABSTRACT**

2 **Purpose:** A subset of patients with post-COVID-19 condition (PCC) fulfill the clinical
3 criteria of myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS). To establish
4 the diagnosis of ME/CFS for clinical and research purposes, comprehensive scores have
5 to be evaluated.

6 **Methods:** We developed the Munich Berlin Symptom Questionnaires (MBSQs) and
7 supplementary scoring sheets (SSSs) to allow for a rapid evaluation of common ME/CFS
8 case definitions. The MBSQs were applied to young patients with chronic fatigue and
9 post-exertional malaise (PEM) who presented to the MRI Chronic Fatigue Center for
10 Young People (MCFC). Trials were retrospectively registered (NCT05778006,
11 NCT05638724).

12 **Results:** Using the MBSQs and SSSs, we report on ten patients aged 11 to 25 years
13 diagnosed with ME/CFS after asymptomatic SARS-CoV-2 infection or mild to moderate
14 COVID-19. Results from their MBSQs and from well-established patient-reported outcome
15 measures indicated severe impairments of daily activities and health-related quality of life.

16 **Conclusions:** ME/CFS can follow SARS-CoV-2 infection in patients younger than 18
17 years, rendering structured diagnostic approaches most relevant for pediatric PCC clinics.
18 The MBSQs and SSSs represent novel diagnostic tools that can facilitate the diagnosis of
19 ME/CFS in children, adolescents, and adults with PCC and other post-viral syndromes.

20 **Keywords:** children, adolescents, ME/CFS, Post-COVID, SARS-CoV-2, post-exertional
21 malaise

Pediatric ME/CFS post-COVID-19 asessed by MBSQs_2023 07 22

22 **Abbreviations**

23 ANA, antinuclear antibodies

24 CCC, Canadian consensus criteria

25 CDC, Centers of Disease Control and Prevention

26 CDW-R, clinical diagnostic worksheet of P.C. Rowe et al. (2017)

27 CFC, Charité Fatigue Center

28 COVID-19, coronavirus disease 2019

29 CRP, C-reactive protein

30 DSQ, DePaul symptom questionnaire

31 EBV, Epstein-Barr virus

32 ECG, electrocardiography

33 EEG, electroencephalography

34 EUROMENE, European Network on ME/CFS

35 GET, graded exercise therapy

36 HR, heart rate

37 HRQoL, health-related quality of life

38 IOM, Institute of Medicine

39 KBV, German National Association of Statutory Health Insurance Physicians

40 MBSQ, Munich Berlin Symptom Questionnaire

41 MCFC, MRI Chronic Fatigue Center for Young People

42 ME/CFS, myalgic encephalomyelitis / chronic fatigue syndrome

43 MRI, TUM university hospital (Klinikum rechts der Isar)

44 MRT, magnetic resonance tomography

45 NICE, National Institute for Health and Care Excellence

46 OH, orthostatic hypotension

47 OI, orthostatic intolerance

48 PASC, post-acute sequelae of COVID-19

49 PCC, post-COVID-19 condition

Pediatric ME/CFS post-COVID-19 asessed by MBSQs_2023 07 22

- 50 PCD-J, pediatric case definition by L.A. Jason et al. (2006)
- 51 PEM, post-exertional malaise
- 52 PFT, pulmonary function testing
- 53 PoTS, postural tachcardia syndrome
- 54 PROM, patient-reported outcome measure
- 55 RT-PCR, reverse transcriptase - polymerase chain reaction
- 56 SARS-CoV-2, severe acute respiratory coronavirus type 2
- 57 SEID, systemic exertion intolerance disease criteria
- 58 SF-36, Short Form 36
- 59 SSS, Supplementary Scoring Sheet
- 60 UCG, ultrasound cardiography
- 61 WHO, World Health Organisation

62

63

64 **What is known**

65 ME/CFS is a frequent debilitating illness. For diagnosis, an extensive differential
66 diagnostic workup is required and the evaluation of clinical ME/CFS criteria. ME/CFS
67 following COVID-19 has been reported in adults but not in pediatric patients younger than
68 19 years of age.

69 **What is new**

70 We present novel questionnaires (MBSQs), as tools to assess common ME/CFS case
71 definitions in pediatric and adult patients with post-COVID-19 condition and beyond. We
72 report on ten patients aged 11 to 25 years diagnosed with ME/CFS following
73 asymptomatic SARS-CoV-2 infection or mild to moderate COVID-19.

74 **INTRODUCTION**

75 The coronavirus disease 2019 (COVID-19) pandemic and its long-term-sequelae elicited
76 an unprecedented healthcare crisis worldwide. Beyond acute morbidity and mortality due
77 to infections with severe acute respiratory coronavirus type 2 (SARS-CoV-2) [1; 2], a
78 plethora of post-acute sequelae of COVID-19 (PASC) (often referred to as Long COVID)
79 with or without major organ damage due to SARS-Cov-2 infection are contributing to the
80 post-pandemic burden and are increasingly challenging healthcare systems and societies
81 [3-7].

82 Most individuals recover from PASC within a few months, but some develop a long-lasting
83 disorder that can severely impair daily function, participation, and health-related quality of
84 life (HRQoL) [4; 8-10]. A post-COVID-19 condition (PCC) (ICD-10 U09.9!) was defined by
85 the World Health Organization (WHO) as continuing or new development of symptoms
86 three months (children: within three months) after the initial SARS-CoV-2 infection, lasting
87 for at least two months and not explained otherwise [11; 12].

88 PASC were estimated to affect at least 65 million individuals worldwide, with a prevalence
89 of about 10% infected cases and a lower prevalence in children compared to adolescents
90 and adults [4; 13]. Estimating pediatric PCC prevalence is still challenging [8; 14], with 0.8
91 to 13% reported in controlled cohorts [15; 16] and 2.0 to 3.5% calculated in a meta-
92 analysis covering initially non-hospitalized children and adolescents [17].

93 COVID-19 sequelae may manifest with a wide variety of symptoms, including fatigue,
94 shortness of breath, cognitive dysfunction, pain, sleep disorder, and/or mood symptoms.

95 These symptoms can persist, fluctuate, or relapse and may have a significant impact on
96 everyday functioning [11; 12; 18-20]. Some patients suffer from exertion intolerance with a
97 worsening of symptoms after mild physical and/or mental activities, known as post-
98 exertional malaise (PEM) [21; 22]. PEM can last for days or weeks and is recognized as a
99 cardinal symptom of myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) [23;
100 24]. ME/CFS following COVID-19 has been reported in adults [21; 25; 26] and in a 19-

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

101 year-old male from the U.S. [27; 28] but, to our knowledge, not yet in younger patients.
102 However, overlapping symptoms of PACS and ME/CFS have been described in pediatric
103 patients [29].

104 ME/CFS is a complex, chronic neurological disorder (ICD-10 G93.3), triggered mostly by
105 infections and rarely by non-infectious life events [30-32]. Core symptoms include reduced
106 daily functioning with fatigue not alleviated by rest, PEM usually lasting more than a day,
107 unrefreshing sleep, neurocognitive deficits ("brain fog") and/or orthostatic intolerance (OI),
108 with additional symptoms in most cases [33]. Hypothesized pathogenic mechanisms of
109 PCC and ME/CFS overlap, including viral persistence, latent virus reactivation,
110 inflammation, autoimmunity, endothelial dysfunction, and microbiome dysbiosis [23; 34].
111 Common risk factors of PCC and ME/CFS are female gender, late adolescence or early
112 adulthood, as well as pre-existing chronic health issues [14; 21; 31; 35; 36].

113 Population-based, pre-pandemic estimates of ME/CFS prevalence ranged from 0.1% to
114 0.89% in adults [37-40] and from 0.75% to 0.98% in adolescents and children [41; 42],
115 with a high number of undetected cases [42]. Current estimates predicted at least a
116 doubling of ME/CFS cases due to severe PCC [21; 27; 34; 43; 44]. A total of 350.000 and
117 400.000 ME/CFS cases were documented in 2018 and 2019, and almost 500.000 cases
118 in 2021 by the German National Association of Statutory Health Insurance Physicians
119 (KBV) [45], with no data for children and adolescents available yet.

120 Since up to now, no reliable diagnostic biomarker for ME/CFS was established, complex
121 disorders with compromising chronic fatigue require a thorough differential diagnostic
122 workup and an evaluation of clinical ME/CFS criteria. Most commonly used are the
123 Canadian consensus criteria (CCC) [46] and the broader criteria established by the former
124 Institute of Medicine (IOM) to define "systemic exertion intolerance disease (SEID)" [47].
125 For children and adolescents, the CCC were adapted by a "pediatric case definition" of
126 L.A. Jason and colleagues (abbreviated here as PCD-J) [48] and in a less restrictive way
127 by the "clinical diagnostic worksheet" designed by P.C. Rowe and colleagues (abbreviated

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

128 here as CDW-R) [49]. A symptom duration of at least six months is usually required for
129 adult patients [31]. It was recently suggested to be reduced cross-age to facilitate early
130 treatment by the National Institute of Health and Care Excellence (NICE) [50]. For children
131 and adolescents, the required disease duration is three months in the CCC as well as the
132 IOM and the PCD-J [46-48].

133 ME/CFS care requires a holistic, longitudinal approach, including extensive patient
134 education, the palliation of symptoms, and adequate psychosocial support. Patients must
135 be carefully guided in "pacing" strategies to avoid PEM ("crashes") [50]. Since graded-
136 exercise strategies (GET) can be harmful to patients with PEM [51] they should not be
137 recommended for patients with ME/CFS [50], although they may be potentially helpful in
138 other forms of PCC [52],

139 Early identification of patients with ME/CFS is crucial in order to avoid mismanagement
140 and secondary damage, including suicidality. With adequate care, ME/CFS can improve in
141 a substantial number of patients, with recovery documented for the majority of affected
142 children and adolescents within ten years [32]. However, recovery does not imply absence
143 of functional impairment [53]. The lack of ME/CFS-specific knowledge among healthcare
144 professionals [54-56], together with an increasing ME/CFS prevalence, renders more
145 patients at risk of insufficient care and secondary disease.

146 A challenge in clinical care and research for ME/CFS is the use of various diagnostic
147 criteria and the lack of specific symptoms. To increase diagnostic sensitivity, the
148 frequency and severity of symptoms should be assessed [57; 58].

149 With the Munich Berlin Symptom Questionnaires (MBSQs) we aimed to facilitate the
150 diagnostic approach to adults, adolescents, and children with chronic fatigue following
151 COVID-19 and beyond. The MBSQs represent novel tools for an age-adapted,
152 standardized evaluation of the most common sets of clinical ME/CFS criteria in clinical
153 and research settings.

Pediatric ME/CFS post-COVID-19 assessed by MBSQs_2023 07 22

154 Here, we present bi-lingual versions of the MBSQs and report on the first ten patients
155 diagnosed with PCC and ME/CFS using the MBSQ in structured medical interviews at our
156 MRI Chronic Fatigue Center For Young People (MCFC). Our Post-COVID clinic was
157 implemented within the MCFC as part of the "Post-COVID Kids Bavaria" project to provide
158 pediatric care and research in the context of severe COVID-19 sequelae [59].

159

160 **PATIENTS AND METHODS**

161 **Inclusion Criteria and Clinical Assessment**

162 Ten patients were diagnosed at the MCFC with PCC and ME/CFS using the German
163 versions of the novel MBSQs and the supplementary scoring sheets (SSSs) (can be
164 requested from authors, for English translation see **Supplementary Materia**) (see full
165 description of the MBSQs below). The collection and publication of medical data from
166 these patients was approved by the TUM Ethics Committee (116/21, 511/21). Written
167 informed consent was obtained from all participants (or parents) prior to inclusion. All
168 patients sought care at the MCFC with a history of confirmed (positive reverse
169 transcription polymerase chain reaction (RT-PCR)) or probable (anti-SARS-CoV-2 IgG
170 without prior COVID-19 vaccination and typical COVID-19 symptoms) SARS-CoV-2
171 infection and with post-viral symptoms lasting for more than three months, in accordance
172 with WHO definitions of the PCC at any age.

173 Before visiting the MCFC, the patients had been asked to complete various
174 questionnaires in a stepped routine process, including well-established patient-reported
175 outcome measures (PROMs) to assess fatigue (Fatigue Severity Scale (FSS) [60] or
176 Chalder Fatigue Scale (CFQ) [61]), PEM (DePaul Symptom Questionnaire - Post-
177 Exertional Malaise (DSQ-PEM)) [24], limitations in daily functioning (Bell Score) [62], and
178 HRQoL during the last four weeks (Short Form-36 Health Survey (SF-36)) [63]. The
179 MBSQ was developed in 2020 and was provided together with other questionnaires prior
180 to the personal visit to the MCFC.

Pediatric ME/CFS post-COVID-19 asessed by MBSQs_2023 07 22

181 The Bell Score measures daily functioning on a scale from 0% to 100%, with 100%
182 representing normal daily functioning [62]. The DSQ-PEM provides a Likert scale for the
183 frequency (0-4) and severity (0-4) of five different PEM-related symptoms and evaluates
184 the duration of PEM [24]. The SF-36 consists of eight dimensions, including i) physical
185 functioning, ii) social functioning, iii) vitality, iv) general health, v) mental health, vi) role
186 physical, vii) role emotional, and viii) bodily pain. The score of each dimension is scaled to
187 0 – 100, with 0 representing the worst and 100 the best health status. The MCFC is
188 focussing on patients with significant fatigue, indicated by a mean score of ≥ 5 (maximum:
189 7) in the FSS [64] or of ≥ 4 (maximum: 11) in the CFQ bimodal score [65] together with
190 long-lasting PEM (≥ 14 hours) and reduced daily functioning.

191 Laboratory and technical investigations were performed at the MCFC and/or prior to
192 admission to exclude other disorders that might explain these symptoms. The panel of
193 analyses was selected depending on the individual symptoms, with a core set of routine
194 analyses in line with prior suggestions [49]. Routine blood analyses included a differential
195 cell count as well as C-reactive protein (CRP), liver, kidney, and thyroid function
196 parameters, HbA1c, total serum immunoglobulins, antinuclear antibodies (ANA),
197 antibodies against thyroid peroxidase (TPO), morning cortisol, antibodies against SARS-
198 CoV-2 and Epstein-Barr virus (EBV), and EBV DNA load in blood and throat washes
199 (PCR), supplemented by analyses of urine and stool (calprotectin, blood). Routine
200 technical investigations included pulmonary function testing (PFT), electrocardiography
201 (ECG), and ultrasound cardiography (UCG). If indicated, electroencephalography (EEG),
202 cardiac or brain magnetic resonance tomography (MRT), ophthalmological and/or
203 rheumatological assessments were added.

204 At the MCFC, patients were seen simultaneously by a pediatrician and psychologist or
205 child and adolescent psychiatrist, each trained in ME/CFS, in order to provide a thorough
206 diagnostic assessment. The pediatrician performed a comprehensive interview and
207 physical examination, the psychologist or psychiatrist carried out the psychological

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

208 evaluation. To assess any OI, including a possible postural orthostatic tachycardia
209 syndrome (PoTS) or orthostatic hypotension (OH), all patients underwent a 10-minute
210 NASA lean test [66]: heart rate (HR) and blood pressure were measured every minute by
211 an electronic device (Carescape V100 Vital Signs Monitor). Patients were asked to hold a
212 supine position for five minutes, then to stand upright and motionless (leaning against the
213 wall with the shoulders and placing the feet two to six inches away from the wall) for ten
214 minutes, and finally to lie down again for five minutes. They were instructed to report any
215 novel symptoms during the whole procedure [49]. The average HR while supine was
216 defined as baseline, and PoTS was defined by a sustained HR ≥ 120 beats per minute
217 (bpm) and/or an increase by HR ≥ 40 bpm for individuals ≤ 19 years and ≥ 30 bpm for
218 individuals > 19 years, together with a history of orthostatic symptoms for at least three
219 months [67; 68]. A psychological evaluation was either provided externally or by
220 psychologists trained in ME/CFS at the MCFC.

221 To establish the ME/CFS diagnosis, clinical criteria were evaluated in semi-structured
222 interviews. The MCFC physician went through the pre-filled MBSQ together with the
223 patient (and his/her parents) to avoid any misunderstanding regarding the presence,
224 frequency, and severity of symptoms as well as the duration of PEM. All answers
225 addressing PEM were carefully re-evaluated, and patients were asked to provide
226 examples of typical PEM triggers and "crashes". The pre-filling procedure at home
227 allowed for taking enough time to answer the questionnaire and enabled the physician to
228 focus on aspects to be clarified during the clinical visit. The MBSQ provides additional
229 space for physician's notes next to each question in the MBSQ. After the visit, the
230 physician filled in the SSS for the respective age group in line with answers consented to
231 in the interview and assessed the various case definitions. A final ME/CFS diagnosis was
232 established if at least one case definition was matched and no other explanation of
233 symptoms arose from adequate diagnostic workup. Each case was discussed in an
234 interdisciplinary ME/CFS board, involving several physicians with ME/CFS expertise.

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

235 **Development of the Munich Berlin Symptom Questionnaire**

236 The MBSQs and SSSs were designed as a joint collaboration of ME/CFS experts from the
237 MCFC in Munich, the Charité Fatigue Center (CFC) in Berlin, the German Association for
238 ME/CFS in Hamburg, and the Research Center CATALPA in Hagen, Germany. They
239 were developed for clinical and research purposes to facilitate the evaluation of diagnostic
240 ME/CFS criteria in a comprehensive, semi-structured personal or telephone interview by
241 physicians trained in ME/CFS.

242 We chose the IOM criteria and CCC, which require a disease duration of at least six
243 months for adults (≥ 18 years) as recommended by the Centers for Disease Control and
244 Prevention (CDC) [69] and the European Network for ME/CFS (EUROMENE) [31],
245 respectively. To keep the MBSQs and SSSs for adults as short as possible, we designed
246 a separate version for children and adolescents (< 18 years) that contained not only
247 questions relevant to the CCC and IOM criteria but also additional questions to assess the
248 PCD-J and CDW-R criteria. For practical reasons, the pediatric version of the MBSQs
249 require three months of disease duration for any case definition, although the CDW-R
250 originally suggested to provide only a preliminary diagnosis after three and a confirmed
251 diagnosis after six months [49] (**Table 1**).

252 We first developed the German versions of the MBSQs and SSSs. All English terms used
253 to describe the symptoms in the original publications [46-49] were attributed to the most
254 adequate of the eight symptom categories of the CCC (fatigue, PEM, sleep disorder, pain,
255 neurocognitive, autonomic, neuroendocrine, and immunologic manifestations). Overlaps
256 and differences were identified, and umbrella terms were introduced if necessary to
257 provide a concise questionnaire. We aimed at the best match of all terms with terms in the
258 original publications and adapted the wording, if necessary, during several rounds of
259 clinical testing and discussion to optimize the understanding by patients and/or parents.
260 To keep the MBSQ as concise as possible, the wording was not adapted for a better
261 understanding for children. The MBSQ was not designed and not evaluated as a patient-

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

262 reported outcome measure (PROM) and therefore is not recommended for use as a
263 PROM. The final German versions were translated back to English, aiming at optimal
264 consistency. The English versions was provided to only few English speaking patients at
265 our centers none of which was included in this report.

266 As suggested in the DSQs by Jason and colleagues [57; 58], we used a 5-point Likert
267 scale for quantifying the frequency and severity of symptoms. In line with the DSQs, the
268 MBSQs require an at least moderate frequency and severity (≥ 2) to support the ME/CFS
269 diagnosis. However, instead of two separate columns for "0" answers regarding severity
270 and frequency in the DSQs, the MBSQs provide a single column to indicate that
271 symptoms were not present. In the MBSQs, four additional questions were provided in a
272 dichotomous format to evaluate the presence or absence of distinct features of fatigue or
273 neurocognitive manifestations. Three further questions provided space for three open
274 answers each to gain information on the prominent triggers of PEM, the main symptoms
275 of PEM, and the most bothering symptoms of ME/CFS. In contrast to the very
276 comprehensive DSQ-2 [58], the MBSQ focuses on ME/CFS symptoms only, omitting any
277 further evaluation of medical history.

278 **RESULTS**

279 We developed the MBSQs and SSSs in German (request from authors) and English
280 **(Supplementary Material)** as novel tools for the clinical assessment of ME/CFS in the
281 context of PCC and beyond. They address the most commonly recommended ME/CFS
282 case definitions (CCC, IOM) and, in the versions for children and adolescents, two
283 additional pediatric case definitions (CDW-R, PCD-J) **(Table 1)** to facilitate semi-
284 structured, age-adapted approaches to diagnosis. Here, we apply the MBSQs and SSSs
285 to patients with PCC and report on the first ten patients diagnosed with ME/CFS according
286 to MBSQ results after a thorough diagnostic workup at our MCFC **(Tables 1 and 2,**
287 **Figures 1 and 2).**

288 The MBSQs were provided to MCFC patients who sought care due to chronic fatigue and
289 PEM. The first ten patients diagnosed with PCC and ME/CFS using the MBSQ included
290 four children and adolescents between 11 and 15 years, and six young adults aged 18 to
291 25 years, with a male-to-female ratio of 3:7. When presenting at the MCFC, these patients
292 were suffering from PCC symptoms for a period of four to 16 months **(Table 2).**

293 9/10 patients were diagnosed with confirmed or probable COVID-19 and 1/10 with
294 asymptomatic SARS-CoV-2 infection between March 2020 and January 2022. 8/10
295 patients provided a positive SARS-CoV-2 RT-PCR result, and 2/10 patients showed
296 SARS-CoV-2 IgG antibodies without prior COVID-19 vaccination, together with a history
297 of COVID-19-like symptoms. 9/10 patients were initially treated as outpatients, while one
298 adult was hospitalized for four days due to a pre-syncopal episode in the context of
299 COVID-19. An initial loss of smell and/or taste was reported by one adolescent and three
300 adults **(Table 2).**

301 Pre-existing medical conditions were present in almost all (9/10) patients, including
302 bronchial asthma (4/10), hypothyroidism (2/10), Grave's disease with hyperthyroidism
303 (1/10), allergies (2/10), attention deficit disorder (1/10), migraine with aura (1/10), history
304 of meningitis (1/10), or Alport's syndrome (1/10) **(Table 2).**

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

305 The comprehensive diagnostic workup did not reveal any other explanation for the
306 reported complex and debilitating symptoms. Physical and neurological examination, as
307 well as ECG and UCG, showed normal findings in all patients. A cardiac MRI performed
308 on an adult patient revealed a condition after perimyocarditis. In two patients, the PFT
309 showed signs of a hyper-responsive bronchial system, one of which reported pre-existing
310 asthma bronchiale. A cranial MRI was indicated by neurologists in nine and an EEG in
311 eight patients, with normal results except a stable, benign, cystic CNS lesion in one and a
312 transient theta wave slowing in another patient. None of these findings were considered to
313 explain the complex symptoms. 9/10 patients complained of OI, with 5/10 patients
314 meeting the diagnostic criteria for PoTS.

315 All patients reported significant fatigue in the FSS (9/9) or CFQ (1/1) and screened
316 positive for PEM in the DSQ-PEM, with a PEM duration of more than 24 hours (**Table 2**).
317 Daily functioning measured by the Bell Score ranged between 20% to 60% (median: 30,
318 IQR: 30 - 48.75). All patients considered their symptoms as very debilitating and had
319 significant difficulties with schooling, apprenticeship, or academic studies.

320 Results from the SF-36 displayed impairment in all dimensions (**Figure 1**) relative to the
321 German norm sample for the age of 14 to 20 years [70]. The physical component
322 summary (PCS) was markedly reduced in our group of ME/CFS patients compared to the
323 German norm population, with a mean score of 24.9 compared to 53.4 ($P < 0.001$). The
324 mean mental component summary score was 44.9 versus 45.0, respectively ($P = 0.982$)
325 [70].

326 All patients experienced substantial reductions in occupational, educational, and/or
327 personal activities, indicated by scoring at or below at least two of the three following
328 subscale cut-offs on the SF-36: role physical ≤ 50 , social functioning ≤ 62.5 , and vitality \leq
329 35, as required by the original CCC and the PCD-J [71]. Compared to patients suffering
330 from mild to moderate depression ($n = 60$, mean age 17.5 ± 1.6 years) [72], our ME/CFS
331 patients had significantly reduced scores in the subscales physical functioning ($P <$

Pediatric ME/CFS post-COVID-19 asessed by MBSQs_2023 07 22

332 0.001), role physical ($P < 0.001$), bodily pain ($P < 0.001$), vitality ($P = 0.002$), and social
333 functioning ($P = 0.016$). Only in the two subscales role emotional ($P < 0.001$) and mental
334 health ($P < 0.001$) our patients scored significantly higher than the control group of
335 adolescents and young adults with moderate to severe depression. The subscale general
336 health was not significantly different ($P = 0.082$) (**Figure 1**).

337 All patients fulfilled at least one ME/CFS case definition addressed in the MBSQ. One
338 child fulfilled the CCC and the PDW-R but not the IOM and the PCD-J. Two adolescents
339 met all four sets of criteria, while one met only the broader PDW-R and IOM criteria. All
340 adults fulfilled the CCC, but one did not match the IOM criteria since sleep was not
341 recognized as "unrefreshing" (**Table 2**).

342 The most common ME/CFS symptoms were fatigue (10/10), limitations in daily life
343 (10/10), long-lasting PEM (10/10), unrefreshing sleep (9/10), neurocognitive
344 manifestations (10/10) (e.g., concentration and memory problems), and dizziness (6/10).
345 The most bothering symptoms, the total amount of symptoms, as well as the frequency
346 and severity of symptoms varied individually (**Table 2, Figure 2**).

347

348 **DISCUSSION**

349 The MBSQs and SSSs are novel, age-adapted, concise diagnostic tools developed to
350 facilitate the evaluation of ME/CFS criteria in patients with fatigue following COVID-19 and
351 beyond. We reported ten young PCC patients who were diagnosed with ME/CFS using
352 the MBSQ. To our knowledge, this is the first report on ME/CFS in people with PCC
353 younger than 18 years.

354 Very little is known about the prevalence of severe PCC in children and adolescents. A
355 survey over a four-week period ending 30 March 2023 on the prevalence of ongoing
356 symptoms following SARS-CoV-2 infection in U.K. households indicated that sequelae
357 defined as "limiting day-to-day activities" manifested less often in children aged 2-11 years

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

358 (0.1%) compared to adolescents and young adults (12-24 years) (0.26 - 0.33%) and
359 adults aged ≥ 25 years (0.46 - 0.92%) [73]. However, early in the pandemic, a report from
360 Sweden indicated that pediatric PCC can compromise school education for several
361 months [74], and a single 19-year-old adolescent with post-COVID-ME/CFS was
362 documented in the US [27; 28]. Meanwhile, additional pediatric patients were diagnosed
363 with ME/CFS at our MCFC and at several partner sites of our recently implemented
364 multicenter long COVID (NCT05638724) and ME/CFS registries (NCT05778006), as will
365 be reported in more detail (unpublished results).

366 ME/CFS, in general, is well documented in children and adolescents [49]. In a pre-
367 pandemic pediatric cohort from Australia, ME/CFS was reported to have followed
368 infections in up to 80% of cases, with EBV infection accounting for 40% of cases [32].
369 12.9%, 7.3%, and 4.3% of adolescents in a pre-pandemic U.S. cohort presented with
370 ME/CFS as defined by the PCD-J criteria at six, 12, and 24 months after EBV-induced
371 infectious mononucleosis [75]. ME/CFS defined by meeting at least one of three case
372 definitions (Fukuda, IOM, CCC) manifested in 23% of U.S. college students following
373 symptomatic primary EBV infection, with 8% of the cohort fulfilling the CCC [76]. The
374 prognosis of ME/CFS was reported to be more favorable in children and adolescents
375 compared to adults, with recovery rates of 38% after five years and 68% after ten years
376 and a mean illness duration of five (range 1–15) years in those who recovered [32]. Post-
377 viral ME/CFS and partial recovery thereof was also documented at the MCFC [77]. Taken
378 together, pediatric ME/CFS following infection with SARS-CoV-2 was not unexpected and
379 might be transient, at least in some cases, if diagnosed and treated in a correct and timely
380 way.

381 Reports of ME/CFS after SARS-CoV-2 infection in adults have been published, including
382 reports from Germany [21; 25; 27]. However, little is known about the pediatric population.
383 To our knowledge, this is the first report on ME/CFS in PCC patients aged less than 18
384 years, including children as young as 11 years. All reported patients had developed long-

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

385 lasting typical symptoms after asymptomatic SARS-CoV-2 infection or mild to moderate
386 courses of documented or probable COVID-19 with no other medical explanation and
387 impairment of daily life, according to the WHO definition of PCC [11]. A substantial
388 reduction in occupational, educational, and/or personal activities of these patients was
389 confirmed by a Bell score of $\leq 60\%$ and by scoring at or below at least two of three
390 subscale cut-offs on the SF-36 (role physical ≤ 50 , social functioning ≤ 62.5 , and vitality \leq
391 35) [71].

392 In line with current evidence indicating a lower prevalence of severe PCC in children
393 younger than 12 years compared to adolescents and adults [73], 9 of 10 of our patients
394 were older than 12 years. At the MCFC, we are regularly seeing young adults up to the
395 age of 20 years since their healthcare needs, in general, do not substantially differ from
396 those of older adolescents and include features such as school or peer group integration
397 that might not be fully covered by healthcare institutions for adult patients. Moreover,
398 patients turning 18 years had been excluded from other pediatric PCC follow-up studies
399 indicating a possible lack of data in this age group [78].

400 The general lack of data regarding ME/CFS following SARS-CoV-2 and other infections
401 may, in part, be explained by insufficient disease-specific knowledge and experience [49;
402 54]. Further, the comparison of published data is challenging due to the different ME/CFS
403 case definitions used worldwide [79; 80]. Thus, harmonization of diagnostic criteria for
404 ME/CFS is urgently needed. High time and cost expenses for the diagnostic workup,
405 moreover, may prevent clinicians from diagnosing ME/CFS and as a result these patients
406 often get no adequate care.

407 The MBSQs and SSSs were developed as concise tools that can facilitate and harmonize
408 diagnostic workup in clinical and research centers currently faced with PCC and other
409 post-infection syndromes. They provide a standardized basis for a semi-structured
410 medical interview. The interview guarantees to rule out any misunderstanding, especially

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

411 concerning PEM, the key feature of ME/CFS. Thus, the MBSQs may be pre-filled by
412 patients at home but should not be used as PROMs.

413 Our approach was based on the DSQs developed as PROMs by L.A. Jason and
414 colleagues to evaluate ME/CFS diagnosis and associated features in studies with adults,
415 adolescents, and children [57]. Like the DSQs, the MBSQs offer Likert scales for the
416 quantification of symptoms, with a threshold of ≥ 2 for both frequency and severity to
417 indicate diagnostic relevance. Moreover, as introduced by the DSQs, the SSSs provide an
418 algorithm to evaluate different case definitions using a single questionnaire.

419 In contrast to the DSQs, the MBSQs neither address demographics nor do they evaluate
420 the medical, occupational, and social history since many PCC centers might want to follow
421 their own respective questionnaires and since some items of the DSQs are related to
422 specific settings in the US. Furthermore, in contrast to the DSQ-2, the MBSQs do not
423 address the comprehensive international consensus criteria (ME-ICC) because they were
424 not recommended by the European Network for ME/CFS (EUROMENE) [31].

425 Importantly, the MBSQs are setting a cut-off at ≥ 14 hours regarding the PEM duration for
426 the CCC as well as for the PCD-J and CDW-R criteria while leaving the IOM criteria
427 without. Previous ME/CFS studies indicated that PEM lasts longer than 24 hours in most
428 patients [24]. Some ME/CFS case definitions required a duration of at least 24 hours,
429 including the CDW-R ("Recovery takes more than 24h") [49]. The original publications of
430 the CCC and the PCD-J stated that "there is a pathologically slow recovery period—usually
431 24 hours or longer" (CCC) [46] and that "the recovery is slow, often taking 24 hours or
432 longer" (PCD-J) [48]), respectively. For the MBSQs, we chose a PEM duration cut-off at \geq
433 14 hours since it included more ME/CFS patients than a cut-off at ≥ 24 hours but still
434 excluded the majority of patients with other chronic diseases in a previous study [24].
435 However, since the MBSQs offer various durations of PEM, they allow for the investigation
436 of subgroups for research purposes.

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

437 The broader IOM criteria included in the MBSQ were recommended for clinical diagnosis
438 by the EUROMENE and by the CDC in the US. The IOM criteria lack, however, a
439 definition of the length of PEM and do not require cognitive symptoms. In PCS, the
440 assessment of the length of PEM is, however, important as it defines subgroups of
441 patients with different biomarker profiles and clinical courses [21; 81-84]. Uniform use of
442 one case definition in clinical practice would allow for reasonable comparability of
443 healthcare data on ME/CFS worldwide, including ME/CFS in the context of PCC.

444 The MBSQs have several limitations. First, results have not been compared with results
445 from other questionnaires investigating ME/CFS case definitions such as e.g. the DSQ-2
446 for reasons of practicability. Patients at the MCFC have to fill in a long list of
447 questionnaires which is challenging many of them to an extent that prevents adding
448 additional questionnaires. However, we are recommending the MBSQs not as a PROM
449 but as a tool to facilitate a structured medical interview which can be recognized as the
450 gold standard for evaluating diagnostic ME/CFS criteria. A comparison of results from pre-
451 filled MBSQs, with MBSQ results from the medical visits as well as with results from other
452 questionnaires, will be an important future goal. Second, the low number and
453 heterogeneity of cases regarding age, gender, and pre-existing morbidity did not allow for
454 correlation and consistency analyses of MBSQ results. This will be aimed at using results
455 from a larger group of future patients. Third and most importantly, a structured medical
456 interview based on well-designed questionnaires cannot substitute for a future diagnostic
457 biomarker for ME/CFS and/or PEM. Without a diagnostic biomarker, diagnosing the
458 complex symptom PEM and PEM duration will remain challenging, especially in patients
459 who are largely preventing long-lasting "crashes" by successful pacing. Last but not least,
460 here we only report on patients who eventually met any ME/CFS case definition. In
461 ongoing studies, we are evaluating the MBSQ in the context of healthy individuals and
462 patients with other chronic diseases.

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

463 Taken together, the MBSQs and SSSs were developed to standardize and accelerate
464 ME/CFS diagnosis at any age in clinical practice and research and were successfully
465 applied to children, adolescents, and young adults with PCC. Standardization in PCC and
466 ME/CFS research is urgently needed to compare clinical studies, identify biomarkers, and
467 eventually select and develop specific treatment approaches [85].
468

469 **Conclusion**

470 We have developed and successfully applied a set of novel diagnostic questionnaire and
471 scoring sheets to identify children, adolescents, and adults with ME/CFS following SARS-
472 CoV-2 infection and beyond. These questionnaires can aid clinicians in assessing up to
473 four case definitions of ME/CFS in a quantitative and standardized manner. The
474 questionnaires include the broader IOM criteria recommended by experts in the U.S. and
475 Europe for clinical care as well as the stricter CCC and, for children and adolescents, two
476 additional pediatric case definitions. These novel tools allow for assessing the frequency
477 and severity of ME/CFS symptoms as well as the duration of PEM and thereby support
478 further research on these features in the context of ME/CFS diagnosis. In sum, we expect
479 the MBSQs to facilitate patient care and research in the context of ME/CFS in pediatrics
480 and beyond.

481

482 **Acknowledgments**

483 We thank all patients who participated in the project as well as their families, for
484 supporting the participation.

485 **REFERENCES**

- 486 1. Pei S, Yamana TK, Kandula S, Galanti M, Shaman J (2021) Burden and characteristics of
487 COVID-19 in the United States during 2020. *Nature* 598:338-341
- 488 2. Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S, Wakefield J (2023) The
489 WHO estimates of excess mortality associated with the COVID-19 pandemic. *Nature*
490 613:130-137
- 491 3. Mueller MR, Ganesh R, Hurt RT, Beckman TJ (2023) Post-COVID Conditions. *Mayo Clin Proc*
492 98:1071-1078
- 493 4. Davis HE, McCorkell L, Vogel JM, Topol EJ (2023) Long COVID: major findings, mechanisms
494 and recommendations. *Nat Rev Microbiol* 21:133-146
- 495 5. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, et al.
496 (2021) Post-acute COVID-19 syndrome. *Nat Med* 27:601-615
- 497 6. Carfi A, Bernabei R, Landi F (2020) Persistent Symptoms in Patients After Acute COVID-19.
498 *Jama* 324:603-605
- 499 7. Han Q, Zheng B, Daines L, Sheikh A (2022) Long-Term Sequelae of COVID-19: A Systematic
500 Review and Meta-Analysis of One-Year Follow-Up Studies on Post-COVID Symptoms.
501 *Pathogens* 11
- 502 8. Zimmermann P, Pittet LF, Curtis N (2022) The Challenge of Studying Long COVID: An Updated
503 Review. *Pediatr Infect Dis J* 41:424-426
- 504 9. Zimmermann P, Pittet LF, Curtis N (2021) How Common is Long COVID in Children and
505 Adolescents? *Pediatr Infect Dis J* 40:e482-e487
- 506 10. Office for National Statistics (2023) Prevalence of ongoing symptoms following coronavirus
507 (COVID-19) infection in the UK: 2 February 2023.
- 508 11. World Health Organization (2023) A clinical case definition for post COVID-19 condition in
509 children and adolescents by expert consensus. World Health Organization

Pediatric ME/CFS post-COVID-19 asessed by MBSQs_2023 07 22

- 510 12. World Health Organization (2021) A clinical case definition of post COVID-19 condition by a
511 Delphi consensus. World Health Organization, Geneva, Switzerland
- 512 13. Scharf RE, Anaya JM (2023) Post-COVID Syndrome in Adults-An Overview. *Viruses* 15
- 513 14. Pellegrino R, Chiappini E, Licari A, Galli L, Marseglia GL (2022) Prevalence and clinical
514 presentation of long COVID in children: a systematic review. *Eur J Pediatr* 181:3995-4009
- 515 15. Molteni E, Sudre CH, Canas LS, Bhopal SS, Hughes RC, Antonelli M, Murray B, Kläser K,
516 Kerfoot E, Chen L, Deng J, Hu C, Selvachandran S, Read K, Capdevila Pujol J, Hammers
517 A, Spector TD, Ourselin S, Steves CJ, Modat M, Absoud M, Duncan EL (2021) Illness
518 duration and symptom profile in symptomatic UK school-aged children tested for SARS-
519 CoV-2. *Lancet Child Adolesc Health* 5:708-718
- 520 16. Stephenson T, Pinto Pereira SM, Shafran R, de Stavola BL, Rojas N, McOwat K, Simmons R,
521 Zavala M, O'Mahoney L, Chalder T, Crawley E, Ford TJ, Harnden A, Heyman I, Swann O,
522 Whittaker E, Consortium C, Ladhani SN (2022) Physical and mental health 3 months after
523 SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national
524 matched cohort study. *Lancet Child Adolesc Health* 6:230-239
- 525 17. Nittas V, Gao M, West EA, Ballouz T, Menges D, Wulf Hanson S, Puhan MA (2022) Long
526 COVID Through a Public Health Lens: An Umbrella Review. *Public Health Rev* 43:1604501
- 527 18. Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, Walshaw C, Kemp S, Corrado
528 J, Singh R, Collins T, O'Connor RJ, Sivan M (2021) Postdischarge symptoms and
529 rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. *J Med*
530 *Virol* 93:1013-1022
- 531 19. Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, O'Connor L, Leavy D, O'Brien
532 K, Dowds J, Sugrue JA, Hopkins D, Martin-Loeches I, Ni Cheallaigh C, Nadarajan P,
533 McLaughlin AM, Bourke NM, Bergin C, O'Farrelly C, Bannan C, Conlon N (2020)
534 Persistent fatigue following SARS-CoV-2 infection is common and independent of severity
535 of initial infection. *PLoS One* 15:e0240784

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

- 536 20. Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, Rodrigues NB, Subramaniapillai M, Di
537 Vincenzo JD, Cao B, Lin K, Mansur RB, Ho RC, Rosenblat JD, Miskowiak KW, Vinberg M,
538 Maletic V, McIntyre RS (2022) Fatigue and cognitive impairment in Post-COVID-19
539 Syndrome: A systematic review and meta-analysis. *Brain Behav Immun* 101:93-135
- 540 21. Kedor C, Freitag H, Meyer-Arndt L, Wittke K, Hanitsch LG, Zoller T, Steinbeis F, Haffke M,
541 Rudolf G, Heidecker B, Bobbert T, Spranger J, Volk H-D, Skurk C, Konietzschke F, Paul F,
542 Behrends U, Bellmann-Strobl J, Scheibenbogen C (2022) A prospective observational
543 study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in
544 Germany and biomarkers associated with symptom severity. *Nature Communications*
545 13:5104
- 546 22. Jason LA, Dorri JA (2022) ME/CFS and Post-Exertional Malaise among Patients with Long
547 COVID. *Neurol Int* 15:1-11
- 548 23. Choutka J, Jansari V, Hornig M, Iwasaki A (2022) Unexplained post-acute infection syndromes.
549 *Nature Medicine* 28:911-923
- 550 24. Cotler J, Holtzman C, Dudun C, Jason LA (2018) A Brief Questionnaire to Assess Post-
551 Exertional Malaise. *Diagnostics (Basel)* 8
- 552 25. Bonilla H, Quach TC, Tiwari A, Bonilla AE, Miglis M, Yang PC, Eggert LE, Sharifi H,
553 Horomanski A, Subramanian A, Smirnoff L, Simpson N, Halawi H, Sum-ping O, Kalinowski
554 A, Patel ZM, Shafer RW, Geng LN (2023) Myalgic Encephalomyelitis/Chronic Fatigue
555 Syndrome is common in post-acute sequelae of SARS-CoV-2 infection (PASC): Results
556 from a post-COVID-19 multidisciplinary clinic. *Front Neurol* 14:1090747
- 557 26. González-Hermosillo JA, Martínez-López JP, Carrillo-Lampón SA, Ruiz-Ojeda D, Herrera-
558 Ramírez S, Amezcua-Guerra LM, Martínez-Alvarado MDR (2021) Post-Acute COVID-19
559 Symptoms, a Potential Link with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A
560 6-Month Survey in a Mexican Cohort. *Brain Sci* 11

Pediatric ME/CFS post-COVID-19 asessed by MBSQs_2023 07 22

- 561 27. Petracek LS, Suskauer SJ, Vickers RF, Patel NR, Violand RL, Swope RL, Rowe PC (2021)
562 Adolescent and Young Adult ME/CFS After Confirmed or Probable COVID-19. *Front Med*
563 (Lausanne) 8:668944
- 564 28. Petracek LS, Broussard CA, Swope RL, Rowe PC (2023) A Case Study of Successful
565 Application of the Principles of ME/CFS Care to an Individual with Long COVID. *Healthcare*
566 (Basel) 11
- 567 29. Jason LA, Johnson M, Torres C (2023) Pediatric Post-Acute Sequelae of SARS-CoV-2
568 infection. *Fatigue: Biomedicine, Health & Behavior*:1-11
- 569 30. Rasa S, Nora-Krukle Z, Henning N, Eliassen E, Shikova E, Harrer T, Scheibenbogen C,
570 Murovska M, Prusty BK (2018) Chronic viral infections in myalgic
571 encephalomyelitis/chronic fatigue syndrome (ME/CFS). *J Transl Med* 16:268
- 572 31. Nacul L, Authier FJ, Scheibenbogen C, Lorusso L, Helland IB, Martin JA, Sirbu CA, et al.
573 (2021) European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
574 (EUROMENE): Expert Consensus on the Diagnosis, Service Provision, and Care of
575 People with ME/CFS in Europe. *Medicina (Kaunas)* 57
- 576 32. Rowe KS (2019) Long Term Follow up of Young People With Chronic Fatigue Syndrome
577 Attending a Pediatric Outpatient Service. *Front Pediatr* 7:21
- 578 33. Estévez-López F, Mudie K, Wang-Steverding X, Bakken IJ, Ivanovs A, Castro-Marrero J, Nacul
579 L, Alegre J, Zalewski P, Słomko J, Strand EB, Pheby D, Shikova E, Lorusso L, Capelli E,
580 Sekulic S, Scheibenbogen C, Sepúlveda N, Murovska M, Lacerda E (2020) Systematic
581 Review of the Epidemiological Burden of Myalgic Encephalomyelitis/Chronic Fatigue
582 Syndrome Across Europe: Current Evidence and EUROMENE Research
583 Recommendations for Epidemiology. *J Clin Med* 9
- 584 34. Komaroff AL, Lipkin WI (2021) Insights from myalgic encephalomyelitis/chronic fatigue
585 syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. *Trends*
586 *Mol Med* 27:895-906

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

- 587 35. Behnood SA, Shafran R, Bennett SD, Zhang AXD, O'Mahoney LL, Stephenson TJ, Ladhani
588 SN, De Stavola BL, Viner RM, Swann OV (2022) Persistent symptoms following SARS-
589 CoV-2 infection amongst children and young people: A meta-analysis of controlled and
590 uncontrolled studies. *J Infect* 84:158-170
- 591 36. Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, Clark A,
592 Ntatsaki E, Vassiliou VS (2023) Risk Factors Associated With Post-COVID-19 Condition: A
593 Systematic Review and Meta-analysis. *JAMA Intern Med* 183:566-580
- 594 37. Nacul LC, Lacerda EM, Pheby D, Campion P, Molokhia M, Fayyaz S, Leite JC, Poland F, Howe
595 A, Drachler ML (2011) Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome
596 (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care.
597 *BMC Med* 9:91
- 598 38. Jason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys AV, Taylor RR, McCready W,
599 Huang CF, Plioplys S (1999) A community-based study of chronic fatigue syndrome. *Arch*
600 *Intern Med* 159:2129-2137
- 601 39. Jason L, Mirin A (2021) Updating the National Academy of Medicine ME/CFS prevalence and
602 economic impact figures to account for population growth and inflation. *Fatigue:*
603 *Biomedicine, Health & Behavior* 9:9-13
- 604 40. Lim E-J, Ahn Y-C, Jang E-S, Lee S-W, Lee S-H, Son C-G (2020) Systematic review and meta-
605 analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis
606 (CFS/ME). *Journal of translational medicine* 18:1-15
- 607 41. Crawley EM, Emond AM, Sterne JAC (2011) Unidentified Chronic Fatigue Syndrome/myalgic
608 encephalomyelitis (CFS/ME) is a major cause of school absence: surveillance outcomes
609 from school-based clinics. *BMJ Open* 1:e000252
- 610 42. Jason LA, Katz BZ, Sunnquist M, Torres C, Cotler J, Bhatia S (2020) The Prevalence of
611 Pediatric Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in a Community-Based
612 Sample. *Child Youth Care Forum* 49:563-579

Pediatric ME/CFS post-COVID-19 asessed by MBSQs_2023 07 22

- 613 43. Mirin AA, Dimmock ME, Jason LA (2022) Updated ME/CFS prevalence estimates reflecting
614 post-COVID increases and associated economic costs and funding implications. *Fatigue:*
615 *Biomedicine, Health & Behavior* 10:83-93
- 616 44. Roessler M, Tesch F, Batram M, Jacob J, Loser F, Weidinger O, Wende D, et al. (2022) Post-
617 COVID-19-associated morbidity in children, adolescents, and adults: A matched cohort
618 study including more than 157,000 individuals with COVID-19 in Germany. *PLoS Med*
619 *19:e1004122*
- 620 45. Kassenärztliche Bundesvereinigung (2023) Öffentliche Anhörung im Ausschuss für Gesundheit
621 des deutschen Bundestages am 19. April 2023. Stellungnahme der KBV zum Antrag der
622 CDU/CSU-Bundestagsfraktion "ME/CFS-Betroffenen sowie deren Angehörigen helfen –
623 Für eine bessere Gesundheits- sowie Therapieversorgung, Aufklärung und Anerkennung.
- 624 46. Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM, Bested AC, Flor-
625 Henry P, Joshi P, Powles ACP, Sherkey JA, van de Sande MI (2003) Myalgic
626 Encephalomyelitis/Chronic Fatigue Syndrome. *Journal of Chronic Fatigue Syndrome* 11:7-
627 115
- 628 47. Clayton EW (2015) Beyond myalgic encephalomyelitis/chronic fatigue syndrome: an IOM report
629 on redefining an illness. *Jama* 313:1101-1102
- 630 48. Jason LA, Jordan K, Miike T, Bell DS, Lapp C, Torres-Harding S, Rowe K, Gurwitt A, De
631 Meirleir K, Van Hoof ELS (2006) A Pediatric Case Definition for Myalgic Encephalomyelitis
632 and Chronic Fatigue Syndrome. *Journal of Chronic Fatigue Syndrome* 13:1-44
- 633 49. Rowe PC, Underhill RA, Friedman KJ, Gurwitt A, Medow MS, Schwartz MS, Speight N, Stewart
634 JM, Vallings R, Rowe KS (2017) Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
635 Diagnosis and Management in Young People: A Primer. *Front Pediatr* 5:121
- 636 50. National Institute for Health and Care Excellence (2021) Myalgic encephalomyelitis (or
637 encephalopathy)/chronic fatigue syndrome: diagnosis and management.

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

- 638 51. Bateman L, Bested AC, Bonilla HF, Chheda BV, Chu L, Curtin JM, Dempsey TT, Dimmock ME,
639 Dowell TG, Felsenstein D, Kaufman DL, Klimas NG, Komaroff AL, Lapp CW, Levine SM,
640 Montoya JG, Natelson BH, Peterson DL, Podell RN, Rey IR, Ruhoy IS, Vera-Nunez MA,
641 Yellman BP (2021) Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of
642 Diagnosis and Management. Mayo Clinic Proceedings 96:2861-2878
- 643 52. National Institute for Health and Care Excellence: Clinical Guidelines (2021) COVID-19 rapid
644 guideline: managing the long-term effects of COVID-19. National Institute for Health and
645 Care Excellence (UK), London, England
- 646 53. Brown MM, Bell DS, Jason LA, Christos C, Bell DE (2012) Understanding long-term outcomes
647 of chronic fatigue syndrome. Journal of clinical psychology 68:1028-1035
- 648 54. Hng KN, Geraghty K, Pheby DFH (2021) An Audit of UK Hospital Doctors' Knowledge and
649 Experience of Myalgic Encephalomyelitis. Medicina (Kaunas) 57
- 650 55. Froehlich L, Hattesoehl DBR, Jason LA, Scheibenbogen C, Behrends U, Thoma M (2021)
651 Medical Care Situation of People with Myalgic Encephalomyelitis/Chronic Fatigue
652 Syndrome in Germany. Medicina (Kaunas) 57
- 653 56. Froehlich L, Niedrich J, Hattesoehl DBR, Behrends U, Kedor C, Haas JP, Stingl M,
654 Scheibenbogen C (2023) Evaluation of a webinar to increase health professionals'
655 knowledge about Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS).
656 Manuscript submitted for publication
- 657 57. Jason LA, Sunnquist M (2018) The Development of the DePaul Symptom Questionnaire:
658 Original, Expanded, Brief, and Pediatric Versions. Front Pediatr 6:330
- 659 58. Bedree H, Sunnquist M, Jason LA (2019) The DePaul Symptom Questionnaire-2: A Validation
660 Study. Fatigue 7:166-179
- 661 59. Bavarian State Ministry of Health and Care (2021) Modellprojekt „Post-COVID Kids Bavaria“.
662 Teilprojekt 2 „Post-COVID Kids Bavaria - PCFC“ (Post-COVID Fatigue Center). Bavarian
663 State Ministry of Health and Care

Pediatric ME/CFS post-COVID-19 asessed by MBSQs_2023 07 22

- 664 60. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The Fatigue Severity Scale:
665 Application to Patients With Multiple Sclerosis and Systemic Lupus Erythematosus.
666 Archives of Neurology 46:1121-1123
- 667 61. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, Wallace EP (1993)
668 Development of a fatigue scale. J Psychosom Res 37:147-153
- 669 62. Bell DS (1994) The doctor's guide to chronic fatigue syndrome: understanding, treating, and
670 living with CFIDS. Da Capo Press
- 671 63. Ware JE, Jr., Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I.
672 Conceptual framework and item selection. Med Care 30:473-483
- 673 64. Lerdal A, Wahl A, Rustoen T, Hanestad BR, Moum T (2005) Fatigue in the general population:
674 a translation and test of the psychometric properties of the Norwegian version of the
675 fatigue severity scale. Scand J Public Health 33:123-130
- 676 65. Jackson C (2015) The Chalder Fatigue Scale (CFQ 11). Occup Med (Lond) 65:86
- 677 66. Lee J, Vernon SD, Jeys P, Ali W, Campos A, Unutmaz D, Yellman B, Bateman L (2020)
678 Hemodynamics during the 10-minute NASA Lean Test: evidence of circulatory
679 decompensation in a subset of ME/CFS patients. J Transl Med 18:314
- 680 67. World Health Organization (2018) ICD-11 MMS. International Classification of Diseases for
681 Mortality and Morbidity Statistics. 8D89.2 Postural orthostatic tachycardia syndrome
- 682 68. Vernino S, Bourne KM, Stiles LE, Grubb BP, Fedorowski A, Stewart JM, Arnold AC, et al.
683 (2021) Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical
684 care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1. Auton
685 Neurosci 235:102828
- 686 69. Centers for Disease Control and Prevotion (2021) Symptoms and Diagnosis of ME/CFS. CDC

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

- 687 70. Bellach B-M, Ellert U, Radoschewski M (2000) Der SF-36 im Bundes-Gesundheitssurvey Erste
688 Ergebnisse und neue Fragen: Erste Ergebnisse und neue Fragen.
689 Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 43:210-216
- 690 71. Jason L, Brown M, Evans M, Anderson V, Lerch A, Brown A, Hunnell J, Porter N (2011)
691 Measuring substantial reductions in functioning in patients with chronic fatigue syndrome.
692 Disabil Rehabil 33:589-598
- 693 72. Kristjánisdóttir J, Olsson GI, Sundelin C, Naessen T (2011) Could SF-36 be used as a
694 screening instrument for depression in a Swedish youth population? Scandinavian journal
695 of caring sciences 25:262-268
- 696 73. Office for National Statistics (2023) Prevalence of ongoing symptoms following coronavirus
697 (COVID-19) infection in the UK: 30 March 2023.
- 698 74. Ludvigsson JF (2021) Case report and systematic review suggest that children may experience
699 similar long-term effects to adults after clinical COVID-19. Acta Paediatr 110:914-921
- 700 75. Katz BZ, Shiraishi Y, Mears CJ, Binns HJ, Taylor R (2009) Chronic fatigue syndrome after
701 infectious mononucleosis in adolescents. Pediatrics 124:189-193
- 702 76. Jason LA, Cotler J, Islam MF, Sunnquist M, Katz BZ (2021) Risks for Developing Myalgic
703 Encephalomyelitis/Chronic Fatigue Syndrome in College Students Following Infectious
704 Mononucleosis: A Prospective Cohort Study. Clin Infect Dis 73:e3740-e3746
- 705 77. Pricoco R, Meidel P, Hofberger T, Zietemann H, Mueller Y, Wiehler K, Michel K, Paulick J,
706 Leone A, Haegele M, Mayer-Huber S, Gerrer K, Mittelstrass K, Scheibenbogen C, Renz-
707 Polster H, Mihatsch L, Behrends U (2023) One-Year Follow-up of Young People with
708 ME/CFS Following Infectious Mononucleosis by Epstein-Barr Virus.
709 medRxiv:2023.2007.2024.23293082
- 710 78. Borch L, Holm M, Knudsen M, Ellermann-Eriksen S, Hagstroem S (2022) Long COVID
711 symptoms and duration in SARS-CoV-2 positive children - a nationwide cohort study. Eur J
712 Pediatr 181:1597-1607

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

- 713 79. VanElzakker MB, Brumfield SA, Lara Mejia PS (2018) Neuroinflammation and Cytokines in
714 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Critical Review of
715 Research Methods. *Front Neurol* 9:1033
- 716 80. Conroy KE, Islam MF, Jason LA (2022) Evaluating case diagnostic criteria for myalgic
717 encephalomyelitis/chronic fatigue syndrome (ME/CFS): toward an empirical case definition.
718 *Disability and Rehabilitation*:1-8
- 719 81. Legler AF, Meyer-Arndt L, Mödl L, Kedor C, Freitag H, Stein E, Hoppmann U, Rust R,
720 Konietschke F, Thiel A, Paul F, Scheibenbogen C, Bellmann-Strobl J (2023) Symptom
721 persistence and biomarkers in post-COVID-19/chronic fatigue syndrome – results from a
722 prospective observational cohort. *medRxiv:2023.2004.2015.23288582*
- 723 82. Sotzny F, Filgueiras IS, Kedor C, Freitag H, Wittke K, Bauer S, Sepulveda N, et al. (2022)
724 Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post
725 COVID Syndrome correlate with symptom severity. *Front Immunol* 13:981532
- 726 83. Haffke M, Freitag H, Rudolf G, Seifert M, Doehner W, Scherbakov N, Hanitsch L, Wittke K,
727 Bauer S, Konietschke F, Paul F, Bellmann-Strobl J, Kedor C, Scheibenbogen C, Sotzny F
728 (2022) Endothelial dysfunction and altered endothelial biomarkers in patients with post-
729 COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). *J Transl Med* 20:138
- 730 84. Flaskamp L, Roubal C, Uddin S, Sotzny F, Kedor C, Bauer S, Scheibenbogen C, Seifert M
731 (2022) Serum of Post-COVID-19 Syndrome Patients with or without ME/CFS Differentially
732 Affects Endothelial Cell Function In Vitro. *Cells* 11
- 733 85. Wong TL, Weitzer DJ (2021) Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue
734 Syndrome (ME/CFS)-A Systemic Review and Comparison of Clinical Presentation and
735 Symptomatology. *Medicina (Kaunas)* 57
- 736

737 **STATEMENTS AND DECLARATIONS**

738 **Funding**

739 This work was supported by the StMGP as well as the Weidenhammer-Zoebele and the
740 Lost-Voices foundations.

741

742 **Competing Interests**

743 U.B. received research grants from the Federal Ministry of Education and Research
744 (BMBF), the Federal Ministry of Health (BMG), the Bavarian Ministry of Health and Care
745 (StMGP), the Bavarian Ministry of Science and Arts (StMWK), the German Center for
746 Infection Research (DZIF), the People for Children (Menschen für Kinder) foundation, the
747 Weidenhammer-Zöbele foundation, the Lost-Voices foundation, and the ME/CFS research
748 foundation.

749 C.S. was consulting Roche, Celltrend, and Bayer; she received support for clinical trials by
750 Bayer, Fresenius, and Miltenyi, honoraria for lectures by Fresenius, AstraZeneca, BMS,
751 Roche, Bayer, and Novartis, and research grants from the German Research Association
752 (DFG), the BMBF, the BMG, the Weidenhammer-Zöbele foundation, the Lost-Voices
753 foundation, and the ME/CFS research foundation.

754 The other authors declare no conflict of interest.

755

756 **Author contribution statement**

757 Conceptualization: L.C.P, K.W., R.P., K.G., J.P., A.L., U.B.. Methodology: L.C.P, K.W.,
758 R.P., K.G., J.P., A.L., C.S., D.H., L.F., U.B.. Data curation, L.C.P., R.P., A.V.. Formal
759 analysis: L.C.P., R.P., L.M. Draft writing: L.C.P, K.W., R.P.. Editing: L.C.P, R.P., M.H.,
760 M.A., A.V., A.L., S.S., S.A., C.W., D.H., L.F., L.M., C.S., U.B.. Figures: R.P., L.M..

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

761 Supervision, U.B.. Acquisition of Funding: U.B.. All authors contributed to the final
762 manuscript. All authors have read and agreed to the published version of the manuscript.

763

764 **Ethical Approval**

765 The study was conducted according to the guidelines of the Declaration of Helsinki and
766 approved by the Ethics Committee of the University Hospital of the Technical University of
767 Munich (116/21, 511/21).

768

769 **Consent to Participate**

770 Written informed consent was obtained from all subjects (or their legal guardian) involved
771 in the study.

772

773 **Data Availability Statement**

774 The data that support the findings of this study are available from the corresponding
775 author, U.B., upon reasonable request.

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

776 TABLES

| <i>Table 1. MBSQ versions for different age groups</i> | | | | | | |
|--|------------------------------------|------------------|------------|------------|--------------|--------------|
| Version | Adressed period of symptoms | Age group | CCC | IOM | PCD-J | CDW-R |
| Children and Adolescents | Past 3 months | 0-17 years | + | + | + | + |
| Adults | Past 6 months | ≥ 18 years | + | + | - | - |

MBSQ, Munich Berlin Symptom Questionnaire;
CCC, Canadian Consensus Criteria, 2003 [46]; IOM, Criteria of the former Institute of Medicine, 2015 [47];
PCD-J, Pediatric Case Definition by Jason et al., 2006 [48]; CDW-R, Clinical Diagnostic Worksheet by Rowe et al., 2017 [49];

Table 2. Clinical Data of Patients with MECFS following SARS-CoV-2 infection


| Patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
|--|---|---|--|--|---|---|--|---|---------------------------------------|---|---|
| Sex | M | M | F | M | F | F | F | F | F | F | |
| Age range (years) | 11-15 | | | | | 18-25 | | | | | |
| COVID-19 | Loss of smell/ taste | - | - | + | - | - | + | + | - | - | + |
| | RT-PCR | + | + | n. d. | + | + | + | + | n. d. | + | + |
| | Antibodies ¹ | + | + | + | n. d. | + | + | n. d. | + | n. d. | + |
| | Medical care | Non-hospitalized | Non-hospitalized | Non-hospitalized | Non-hospitalized | Non-hospitalized | Hospitalized | Non-hospitalized | Non-hospitalized | Non-hospitalized | Non-hospitalized |
| Latency period from infection to medical evaluation (months) | 10 | 14 | 16 | 4 | 10 | 10 | 13 | 14 | 11 | 9 | |
| Post-COVID | Main symptoms as prioritized by the patient | 1. Dizziness 2. Tiredness 3. Pain | 1. Concentration problems 2. Dizziness 3. Thermostatic instability | 1. Fatigue 2. PEM 3. Neurocognitive manifestations | 1. Headaches 2. Concentration problems 3. Dizziness | 1. Concentration problems 2. Fatigue 3. Headaches/dizziness | 1. Brain fog 2. Headaches 3. PEM | 1. Pain 2. Fatigue 3. Neurocognitive manifestations | 1. Fatigue 2. Pain 3. Dizziness | 1. Fatigue 2. Flu-like feeling 3. PEM | 1. Breathing problems 2. Malaise with mild fever 3. Fatigue/tiredness |
| | OI/PoTS/OH | OI | PoTS | OI | PoTS | OI | PoTS | PoTS | OI | - | PoTS |
| PROMs | Bell Score ² | 50-60 | 20 | 30 | 30 | 30 | 20-30 | 30 | 60 | 50 | 40-50 |
| | FSS ³ | 5.6 | 6.3 | 6.6 | 6.6 | 7.0 | 6.9 | 6.6 | n. d. | 6.0 | 6.8 |
| | CFQ ⁴ | n. d. | n. d. | n. d. | n. d. | n. d. | n. d. | n. d. | 11 | n. d. | n. d. |
| | DSQ-PEM | + | + | + | + | + | + | + | + | + | + |
| MBSQs | CCC | + | - | + | + | + | + | + | + | + | + |
| | IOM | - | + | + | + | + | + | + | + | - | + |
| | PCD-J | - | - | + | + | n. d. | n. d. | n. d. | n. d. | n. d. | n. d. |
| | CDW-R | + | + | + | + | n. d. | n. d. | n. d. | n. d. | n. d. | n. d. |
| | PEM duration (hours) | > 24 | > 24 | > 24 | > 24 | > 24 | > 24 | > 24 | > 24 | > 24 | > 24 |

M: male; F: female; RT-PCR: reverse transcription polymerase chain reaction; n. d.: not done; PEM: post-exertional malaise; MRT: magnetic resonance tomography; PFT: pulmonary function testing; EEG: electroencephalography; PoTS: postural orthostatic tachycardia syndrome; OI: orthostatic intolerance; OH: orthostatic hypotension; PROMs: patient-reported outcome measures; FSS: Fatigue Severity Scale, mean score; CFQ: Chalder Fatigue Scale, bimodal score; DSQ-PEM: DePaul Symptom Questionnaire-Post-Exertional Malaise; MBSQs: Munich Berlin Symptom Questionnaires; CCC = Canadian Consensus Criteria, [46]; IOM: Criteria of the former Institute of Medicine [47]; PCD-J: Pediatric Case Definition by Jason et al. [48]; CDW-R: Clinical Diagnostic Worksheet by Rowe et al. [49]; hrs: hours; ¹ anti-SARS-CoV-2 spike antibodies before vaccination and/or anti-SARS-CoV-2 nucleocapsid antibodies; ² Bell Score (%) (0% = entirely bedridden; 100% = normal daily functioning); ³ FSS (maximum value: 7); ⁴ CFQ (maximum value: 11)

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

777 **FIGURES**

778 **Figure 1. Results from the Short Form 36 Health Survey (SF-36)**



779

780 *Spider diagrams display the different dimensions of the Short Form 36 Health Survey (SF-*
781 *36) for the ten MCFC patients with ME/CFS following COVID-19 (Post-COVID-ME/CFS),*
782 *the German norm population (age 14 – 20 years) from 1998 [70], and patients with*
783 *moderate to severe depression (n = 60, mean age 17.5±1.6 years) [72].*

784

785

786

787

788

789

790

791

792

793

794


795

796

797

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

798 **Figure 2a. Frequency and Severity of Symptoms**



799
 800 *Stacked bar charts represent the frequency and severity of symptoms as indicated on the*
 801 *first page of the Munich Berlin Symptom Questionnaires (MBSQs). Symptoms that are*
 802 *assessed differently in pediatric (n = 4) and adult patients (n = 6) are presented*
 803 *separately, as indicated.*

804

805

806


807

808

809

810 **Figure 2b. Frequency and Severity of Symptoms**

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22



811

812 *Stacked bar charts display the frequency and severity of symptoms from the second page*

813 *of the Munich Berlin Symptom Questionnaires (MBSQs). Symptoms that are assessed*

814 *differently in pediatric (n = 4) and adult patients (n = 6) are presented separately, as*

815 *indicated. *New difficulties with math or other educational subject; **Marked weight*

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

- 816 *change and / or loss of appetite and / or abnormal appetite; ***New sensitivities to food,*
817 *medication or chemicals.*